June 11th, China Biopharmaceuticals announced that the Group developed the treatment of AIDS drug Entrita-Nofove tablets (commodity name: Keai Ke) has been issued by the State Drug Administration drug registration approval, for the variety of generic drugs in the first domestic approval, and as the same through the consistency evaluationEnquata binte Nofovir tablets are used to treat HIV-1 infection in adults and children over the age of 12 (including) and were originally used as GileadAccording to Minnet.com, Enqual binti Nofovir has global sales of $2.8 billion in 2019.
The data showed that the Enquati Nofovir tablet contained two active ingredients - Enquatabin and Fumatonove di pisters, both of which were highly effective antiretroviral drugsEnquata binte Nofovir tablets as a single tablet, with simplified treatment, significant efficacy, high patient drug response, low drug resistance and so on, has been included in the 2017 edition of the National Health Insurance Directory.
Gilead's N'Gotle Stakes Global Sales (MILLIONS) Minnet.com data show that Gilead's N'Tatum-BenfredNovir sales have fallen year-on-year in recent years, from $3.566 billion in 2016 to $2.813 billion in 2019In China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal Enquata Binti Nofowe sales in 2019 46.63 million yuan, an increase of 86.59 percent year-on-year.
Zhengda Tianqing Pharmaceutical Group Enqutha Binti Nofowei film review timeline up to now, the product also has Qilu Pharmaceutical, Sichuan Haicisco, Anhui Baker Biopharmaceutical imitation 4 categories of listing applications are being reviewed and approved, once approved will be treated as consistent evaluation.
China Biopharma said that there is no domestic Enta binti Noforwei tablet generic sase on the market, the original research and import products are expensive, greatly increase the cost of drug use for patients, it is difficult to have universalThe approval of this heavy product will expand the clinical drug options for the treatment of HIV-1, reduce the burden of drug use for patients, and have broad market prospects.
Source: Public Company Announcement, Minnet Database